AgeX Therapeutics Inc. (AGE) and Midatech Pharma Plc (NASDAQ:MTP) Comparison side by side

This is therefore a contrasting of the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation in AgeX Therapeutics Inc. (NYSEAMERICAN:AGE) and Midatech Pharma Plc (NASDAQ:MTP). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AgeX Therapeutics Inc. 1.54M 94.99 10.40M -0.21 0.00
Midatech Pharma Plc N/A 0.00 N/A -0.85 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for AgeX Therapeutics Inc. and Midatech Pharma Plc.


Table 2 shows the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
AgeX Therapeutics Inc. -675.32% -82% -63.9%
Midatech Pharma Plc 0.00% 0% 0%

Insider and Institutional Ownership

Institutional investors owned 23.8% of AgeX Therapeutics Inc. shares and 0% of Midatech Pharma Plc shares. Insiders owned 43.8% of AgeX Therapeutics Inc. shares. On the other hand, insiders owned about 32.1% of Midatech Pharma Plc’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AgeX Therapeutics Inc. 0.44% 2.24% 11.22% 0% 0% 52.51%
Midatech Pharma Plc -21.05% -30.38% 48.92% -56.58% -79.38% 6.45%

For the past year AgeX Therapeutics Inc.’s stock price has bigger growth than Midatech Pharma Plc.


AgeX Therapeutics Inc. beats on 5 of the 9 factors Midatech Pharma Plc.

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. The company also engages in the marketing of Ferralet 90, a prescription iron supplement for the treatment of anemias that are responsive to oral iron therapy; and Aquoral, an artificial saliva spray to provide relief from chemotherapy/radiation therapy. In addition, it is involved in the research and development of various product candidates in the areas of oncology and neuroscience, including ophthalmology; and immunotherapy. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.